手机购彩

China's self-developed anti-cancer drug pirlotinib tops international top magazines again
Today, the Phase II clinical study of the national class 1.1 anti-tumor innovative drug pirlotinib, completed by the director of the National Cancer Center / Xu Binghe of the Cancer Hospital of the Chinese Academy of Medical Sciences and supported by the national major new drug creation program, was officially published in JCO. American Journal of Clinical Oncology), impact factor 28.245 points
2019-08-23
New breakthrough in nasopharyngeal cancer treatment
Xinhuanet, Beijing, September 29 (Wang Kunshuo) China is a high incidence of nasopharyngeal cancer. According to WHO data, China's nasopharyngeal cancer patients rank first in the world. Among them, the incidence of Guangdong is more than five times the national average, so nasopharyngeal cancer is known as "Guangdong cancer". Recently, new treatments have been made for this high-risk cancer in China.
2018-10-08
Breakthrough in HER2-positive advanced breast cancer targeted drugs in China
According to the information from the website of the State Drug Administration on the 16th, China's self-developed new drug pirlotinib maleate (Ireni) for the treatment of relapsed or metastatic breast cancer was approved for marketing.
2018-08-18
Jiangsu Manufacturing Insights: Decades of Deep Plowing Industry Drive Innovation to Climb "Everest"
China News Network, Jiangsu News, July 24 (Reporter Yu Congwen) Xugong has been focusing on construction machinery manufacturing for 40 years, and regards the top three manufacturers in the world's construction machinery manufacturing industry as "the summit of Mount Everest"; Hengrui Medicine has no heart for 48 years Poon focuses on medicines and has invested billions of yuan in innovation research and development, in order to establish a national pharmaceutical brand and relieve the suffering of Chinese people. Recently, the reporter followed the "reformation and development of high quality ...
2018-07-25
How did Hengrui Medicine turn into an innovative medicine leader A-share medicine “how to make a brother in market value”?
In the A-share market, there is such a "white horse" company: In the 17 years since its listing, net profit has only slightly decreased by 2.17% in 2002, and the remaining 16 years have achieved positive growth, with a compound annual growth rate of 25.94%; in the last 10 years, net asset income The rate has been kept above 21%, and the profitability is very eye-catching. In 2016, it was selected as "the first batch of national top 100 innovative companies in pilot projects" and became the only one of the first 9 innovative companies ...
2018-07-04